EpiEndo Pharmaceuticals

Pharmaceutical ManufacturingReykjavík, Iceland11-50 Employees

EpiEndo Pharmaceuticals is a clinical-stage Icelandic biopharmaceutical company that targets impairment of epithelial barriers as a shared driver of inflammation in the airways, gastrointestinal tract, and skin. Based in Reykjavík and founded in 2014, the company pursues barrier-modulating approaches to address chronic inflammatory diseases. It is advancing oral therapeutics such as glasmacinal, a macrolide candidate with reduced antimicrobial resistance potential.

Its intended beneficiaries are patients with chronic inflammatory conditions affecting the respiratory system and related tissues, with clinicians who treat these disorders. The company collaborates with academic institutions to advance its programs, including a partnership with Lund University to study EP395, a non-antibiotic macrolide that may enhance antiviral responses in bronchial epithelial cells. In the clinical-stage pharmaceutical sector, EpiEndo positions itself around a novel class of barrier-enhancing, anti-inflammatory therapies for respiratory disease, underpinned by ongoing research and collaborations.

Sign up for free to view info

Email Format Employee directory